Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study

• Main Authors: Yuemei Hu (Author), Kai Chu (Author), Nathalie Lavis (Author), Xiaoling Li (Author), Bill Liang (Author), Shuzhen Liu (Author), Ming Shao (Author), Jean-Denis Shu (Author), Cynthia Tabar (Author), Sandrine Samson (Author)
• Format: Book
• Published: Taylor & Francis Group, 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Seasonal influenza causes substantial morbidity and mortality in China, which largely results from limited vaccine accessibility and poor vaccination coverage. Since 2013, Sanofi Pasteur's facilities in Shenzhen, China have produced a trivalent inactivated influenza vaccine (Shz-IIV3) for each...